A McKenna

BA Walker

BGM Durie

CJ Sigrist

GV Long

H Ekedahl

International Myeloma Working Group

J Blade

JA McCubrey

JB Egan

JG Lohr

JJ Keats

JP Sharman

K Cibulskis

K Misund

K Wang

M Andrulis

M Griffith

MA Chapman

MH Rosove

OL Bohn

PB Chapman

RD Finn

S Dietrich

S Jang

S Peters

SA Forbes

UniProt Consortium

X Liu

Blood Cancer Journal

AbstractIn this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF V600E by allele-specific real-time PCR (AS-PCR). Positive results were confirmed by immunohistochemistry, Sanger sequencing and, in three patients from whom we had stored purified myeloma cells, whole-exome sequencing. Eleven patients (5.3%) were BRAF V600E mutation positive by AS-PCR and at least one other method. The fraction of mutated cells varied from 4 to 100%. BRAF V600E-positive patients had no characteristic clinical phenotype except for significantly higher levels of serum creatinine (125 versus 86 μmol/l) Seven of eleven patients responded with at least very good partial response to alkylators, immunomodulatory agents or proteasome inhibitors. Progression-free and overall survival were similar in patients with and without the mutation. By this integrated approach, we found that patients with BRAF V600E mutation responded very well to broad acting drugs and there was no relation to prognosis in early-stage myeloma. In particular, a large mutated cell fraction did not correlate with aggressive disease.</jats:p

E H Rustad

H Y Dai

H Hov

E Coward

V Beisvag

O Myklebost

E Hovig

S Nakken

D Vodák

L A Meza-Zepeda

A K Sandvik

K F Wader

A Sundan

H Aarset

A Waage

Crossref

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

Abstract

Similar works

Full text

Available Versions

Crossref